A carregar...
A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma
BACKGROUND: The KRAS oncogene is a driver mutation and is present in greater than 90% of pancreatic ductal adenocarcinomas (PDAC). A subset of these tumors, however, do not harbor mutations in KRAS (wild type KRAS). Studies have shown that patients with mutated KRAS have a poorer survival on first-l...
Na minha lista:
| Publicado no: | J Gastrointest Oncol |
|---|---|
| Main Authors: | , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
AME Publishing Company
2018
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5848049/ https://ncbi.nlm.nih.gov/pubmed/29564165 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2017.10.14 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|